|
|
免疫治疗在胃癌新辅助治疗中的研究进展
|
Abstract:
胃癌(GC)是世界乃至中国最常见的恶性肿瘤之一，其具有异质性高、预后差等特点。手术治疗显著提高了局部晚期胃癌患者的预后。但术后复发率仍然较高，患者长期生存欠佳。临床上无远处转移、临床评估为可手术切除的T2以上或伴有淋巴结转移的患者，首选新辅助化学治疗或新辅助放化学治疗，近年来随着免疫治疗的不断深入研究及其在临床中的广泛应用，越来越多的患者在免疫治疗作为新辅助治疗的治疗方案中获益，从而将免疫治疗纳入指南。基于免疫治疗在新辅助环境中的广泛应用，胃癌的新辅助免疫治疗方案也不断得以调整和完善。随着免疫治疗药物和技术的不断创新与精进，胃癌治疗也逐渐向精准化方向发展，在挫折中不断成长。本文综述了近年来免疫治疗在胃癌新辅助治疗中的研究进展。
Gastric cancer (GC) is one of the most common malignant tumors in the world and even in China, which is characterized by high heterogeneity and poor prognosis. Surgical treatment significantly improves the prognosis of patients with locally advanced gastric cancer. However, the postoperative recurrence rate is still high, and the long-term survival of patients is poor. Neoadjuvant chemotherapy or neoadjuvant radiotherapy is the first choice for patients with no distant metastasis clinically and clinically assessed as T2 or above that can be resectable or accompanied by lymph node metastasis. In recent years, with the continuous in-depth study of immunotherapy and its wide application in clinical practice, more and more patients benefit from immunotherapy as a treatment plan of neoadjuvant therapy, so immunotherapy is included Guidelines. Based on the widespread use of immunotherapy in neoadjuvant settings, neoadjuvant immunotherapy regimens for gastric cancer are constantly being adjusted and refined. With the continuous innovation and improvement of immunotherapy drugs and technologies, the treatment of gastric cancer has gradually developed in the direction of precision, and has continued to grow in setbacks. This article reviews the progress of immunotherapy in neoadjuvant therapy for gastric cancer in recent years.
| [1] | Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660 |
| [2] | Smyth, E.C., Nilsson, M., Grabsch, H.I., van Grieken, N.C. and Lordick, F. (2020) Gastric Cancer. The Lancet, 396, 635-648. https://doi.org/10.1016/s0140-6736(20)31288-5 |
| [3] | 闫超, 陕飞, 李子禹. 2020年全球胃癌负担分析: 聚焦中国流行现状[J]. 中国肿瘤, 2023, 32(3): 161-170. |
| [4] | Siegel, R.L., Giaquinto, A.N. and Jemal, A. (2024) Cancer Statistics, 2024. CA: A Cancer Journal for Clinicians, 74, 12-49. https://doi.org/10.3322/caac.21820 |
| [5] | Choi, S., Kim, N., Park, J.H., Nam, R.H., Song, C. and Lee, H.S. (2022) Effect of Helicobacter pylori Infection and Its Eradication on the Expression of Tight Junction Proteins in the Gastric Epithelium in Relation to Gastric Carcinogenesis. Helicobacter, 27, e12929. https://doi.org/10.1111/hel.12929 |
| [6] | Duell, E.J., Travier, N., Lujan-Barroso, L., Clavel-Chapelon, F., Boutron-Ruault, M., Morois, S., et al. (2011) Alcohol Consumption and Gastric Cancer Risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) Cohort. The American Journal of Clinical Nutrition, 94, 1266-1275. https://doi.org/10.3945/ajcn.111.012351 |
| [7] | Larsson, S.C., Bergkvist, L. and Wolk, A. (2006) Fruit and Vegetable Consumption and Incidence of Gastric Cancer: A Prospective Study. Cancer Epidemiology, Biomarkers & Prevention, 15, 1998-2001. https://doi.org/10.1158/1055-9965.epi-06-0402 |
| [8] | Shikata, K., Kiyohara, Y., Kubo, M., Yonemoto, K., Ninomiya, T., Shirota, T., et al. (2006) A Prospective Study of Dietary Salt Intake and Gastric Cancer Incidence in a Defined Japanese Population: The Hisayama Study. International Journal of Cancer, 119, 196-201. https://doi.org/10.1002/ijc.21822 |
| [9] | Smyth, E.C., Capanu, M., Janjigian, Y.Y., Kelsen, D.K., Coit, D., Strong, V.E., et al. (2012) Tobacco Use Is Associated with Increased Recurrence and Death from Gastric Cancer. Annals of Surgical Oncology, 19, 2088-2094. https://doi.org/10.1245/s10434-012-2230-9 |
| [10] | Hasegawa, H., Shitara, K., Takiguchi, S., Takiguchi, N., Ito, S., Kochi, M., et al. (2022) A Multicenter, Open-Label, Single-Arm Phase I Trial of Neoadjuvant Nivolumab Monotherapy for Resectable Gastric Cancer. Gastric Cancer, 25, 619-628. https://doi.org/10.1007/s10120-022-01286-w |
| [11] | 张栩晨. PD-1抑制剂联合化疗对比单纯化疗新辅助治疗局部晚期胃癌的疗效和安全性分析[D]: [硕士学位论文]. 青岛: 青岛大学, 2023. |
| [12] | Golchin, S., Alimohammadi, R., Rostami Nejad, M. and Jalali, S.A. (2019) Synergistic Antitumor Effect of Anti‐PD-L1 Combined with Oxaliplatin on a Mouse Tumor Model. Journal of Cellular Physiology, 234, 19866-19874. https://doi.org/10.1002/jcp.28585 |
| [13] | Salas-Benito, D., Pérez-Gracia, J.L., Ponz-Sarvisé, M., Rodriguez-Ruiz, M.E., Martínez-Forero, I., Casta？ón, E., et al. (2021) Paradigms on Immunotherapy Combinations with Chemotherapy. Cancer Discovery, 11, 1353-1367. https://doi.org/10.1158/2159-8290.cd-20-1312 |
| [14] | Yin, Y., Lin, Y., Yang, M., Lv, J., Liu, J., Wu, K., et al. (2022) Neoadjuvant Tislelizumab and Tegafur/Gimeracil/Octeracil (S-1) plus Oxaliplatin in Patients with Locally Advanced Gastric or Gastroesophageal Junction Cancer: Early Results of a Phase 2, Single-Arm Trial. Frontiers in Oncology, 12, Article ID: 959295. https://doi.org/10.3389/fonc.2022.959295 |
| [15] | Yuan, S., Nie, R., Jin, Y., Liang, C., Li, Y., Jian, R., et al. (2024) Perioperative Toripalimab and Chemotherapy in Locally Advanced Gastric or Gastro-Esophageal Junction Cancer: A Randomized Phase 2 Trial. Nature Medicine, 30, 552-559. https://doi.org/10.1038/s41591-023-02721-w |
| [16] | Tang, X., Li, M., Wu, X., Guo, T., Zhang, L., Tang, L., et al. (2022) Neoadjuvant PD-1 Blockade Plus Chemotherapy Induces a High Pathological Complete Response Rate and Anti-Tumor Immune Subsets in Clinical Stage III Gastric Cancer. OncoImmunology, 11, Article ID: 2135819. https://doi.org/10.1080/2162402x.2022.2135819 |
| [17] | Wang, X., Huang, J., Huang, H., Liu, Y., Ji, C. and Liu, J. (2023) Safety and Efficacy of Immunotherapy plus Chemotherapy as Neoadjuvant Treatment for Patients with Locally Advanced Gastric Cancer: A Retrospective Cohort Study. Investigational New Drugs, 41, 579-586. https://doi.org/10.1007/s10637-023-01379-y |
| [18] | Tang, Z., Wang, Y., Liu, D., Wang, X., Xu, C., Yu, Y., et al. (2022) The Neo-Planet Phase II Trial of Neoadjuvant Camrelizumab plus Concurrent Chemoradiotherapy in Locally Advanced Adenocarcinoma of Stomach or Gastroesophageal Junction. Nature Communications, 13, Article No. 6807. https://doi.org/10.1038/s41467-022-34403-5 |
| [19] | Wei, J., Lu, X., Liu, Q., Fu, Y., Liu, S., Zhao, Y., et al. (2023) Neoadjuvant Sintilimab in Combination with Concurrent Chemoradiotherapy for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-Arm Phase 2 Trial. Nature Communications, 14, Article No. 4904. https://doi.org/10.1038/s41467-023-40480-x |
| [20] | Li, C., Zheng, Y., Shi, Z., Yang, L., Zhang, B., Wang, Z., et al. (2023) 1512MO Perioperative Camrelizumab (C) Combined with Rivoceranib (R) and Chemotherapy (Chemo) versus Chemo for Locally Advanced Resectable Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma: The First Interim Analysis of a Randomized, Phase III Trial (DRAGON Iv). Annals of Oncology, 34, S852. https://doi.org/10.1016/j.annonc.2023.09.1425 |
| [21] | Cascone, T., William, W.N., Weissferdt, A., Leung, C.H., Lin, H.Y., Pataer, A., et al. (2021) Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Operable Non-Small Cell Lung Cancer: The Phase 2 Randomized NEOSTAR Trial. Nature Medicine, 27, 504-514. https://doi.org/10.1038/s41591-020-01224-2 |
| [22] | Shen, P., Qiao, B., Jin, N. and Wang, S. (2022) Neoadjuvant Immunoradiotherapy in Patients with Locally Advanced Oral Cavity Squamous Cell Carcinoma: A Retrospective Study. Investigational New Drugs, 40, 1282-1289. https://doi.org/10.1007/s10637-022-01293-9 |
| [23] | 杨盈赤, 庞凯, 张忠涛. 新辅助放疗联合免疫治疗对直肠癌微创术式应用的影响[J]. 外科理论与实践, 2023, 28(3): 186-189. |
